Scientific article
OA Policy
English

Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms

Published in

Circulation, vol. 103, no. 4, p. 544-548

Publication date

2001

Abstract

Inhaled nitric oxide (iNO) has been used to assess the vasodilator capacity of the pulmonary vascular bed in children with congenital heart disease and elevated pulmonary vascular resistance. Inhaled iloprost is a pulmonary vasodilator for the long-term treatment of pulmonary hypertension (PHT). Because these 2 vasodilators act through different pathways (release of cGMP or cAMP, respectively), we compared the pulmonary vasodilator capacity of each.

Keywords

  • Administration, Inhalation
  • Aerosols
  • Analysis of Variance
  • Child
  • Child, Preschool
  • Cyclic AMP/blood
  • Cyclic GMP/blood
  • Heart Defects, Congenital/complications
  • Hemodynamics/drug effects
  • Humans
  • Hypertension, Pulmonary/drug therapy/etiology/physiopathology
  • Iloprost/administration & dosage
  • Infant
  • Lung/blood supply/drug effects/physiopathology
  • Nitric Oxide/administration & dosage
  • Pulmonary Circulation/drug effects
  • Vascular Resistance/drug effects
  • Vasodilator Agents/administration & dosage

Citation (ISO format)

RIMENSBERGER, Peter et al. Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms. In: Circulation, 2001, vol. 103, n° 4, p. 544–548. doi: 10.1161/01.CIR.103.4.544

Main files (1)

Article (Published version)

Identifiers

Journal ISSN

0009-7322
621views
536downloads

Technical informations

Creation

11/03/2015 14:48:00

First validation

11/03/2015 14:48:00

Update

14/03/2023 23:01:27

Status update

14/03/2023 23:01:27

Last indexation

30/10/2024 23:30:10
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated